{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:14:06Z","timestamp":1787019246699,"version":"build-2736575974"},"reference-count":26,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Objectives: To scrutinize the therapeutic efficiency and safety profile of lenvatinib, accompanied by the programmed cell death protein-1 (PD-1) monoclonal antibody, and interventional treatment in managing intermediate-stage hepatocellular carcinoma. Methods: Retrospective analysis was performed on clinical data from 93 patients suffering from intermediate to advanced hepatocellular carcinoma, treated at our institution from May 2018 to April 2020. Patients were divided based on the therapeutic regimen: 43 cases constituted the control group receiving lenvatinib plus transhepatic artery chemoembolization (TACE), while the remaining 50 cases in the study group were managed with lenvatinib, PD-1 monoclonal antibody, and TACE. Outcome measures included therapeutic efficacy, tumor markers (carcinoembryonic antigen [CEA], alpha-fetoprotein [AFP], \u03b1-L-fucosidase [AFU], carbohydrate antigen 199 [CA199]), immune response indices (CD3+, CD4+, CD8+, CD4+\/CD8+ ratio), pertinent cytokine levels (vascular endothelial growth factor [VEGF], matrix metalloproteinase-9 [MMP-9], basic fibroblast growth factor [aFGF], acidic fibroblast growth factor [bFGF]), quality of life (as per Quality of Life Assessment Scale for Cancer Patients [QOL-LC] scores), adverse effects, and survival rates. Results: The study group exhibited a significantly enhanced total effective rate compared to the control group (74.00% vs 53.49%, P\u2009&lt;\u2009.05). Post-treatment levels of CEA, AFP, AFU, CA199, CD8+, VEGF, MMP-9, aFGF, and bFGF were notably lower in both groups, particularly in the study group. Contrastingly, CD3+, CD4+, CD4+\/CD8+ratios, and QOL-LC scores were substantially elevated in the study group ( P\u2009&lt;\u2009.05). Adverse reaction prevalence was analogous between 2 groups (27.91% vs 26.00%; P\u2009&gt;\u2009.05). Moreover, the study group reported significantly higher 1-, 2-, and 3-year survival rates than the control group ( P\u2009&lt;\u2009.05). Conclusion: The combined use of lenvatinib, PD-1 monoclonal antibody, and interventional treatment for intermediate to advanced hepatocellular carcinoma may have a definitive therapeutic efficacy. This regimen is effective in reducing tumor marker levels, enhancing immune function, modulating VEGF, MMP-9, and other related cytokine levels, and improving patients\u2019 quality of life without significantly augmenting adverse effects. This treatment paradigm also contributes to increased survival rates and promises favorable prognosis.<\/jats:p>","DOI":"10.1177\/15330338241256812","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:04:46Z","timestamp":1716854686000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Lenvatinib in Combination With PD-1 Monoclonal Antibody and Interventional Treatment for Intermediate-Stage Hepatocellular Carcinoma: Impact on Serum Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 Levels: A Retrospective Study"],"prefix":"10.1177","volume":"23","author":[{"given":"Jianyong","family":"Zhu","sequence":"first","affiliation":[{"name":"Senior Department of Hepato-Pancreato-Biliary Surgery, The First Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yintao","family":"Wu","sequence":"additional","affiliation":[{"name":"Senior Department of Hepato-Pancreato-Biliary Surgery, The First Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepato-Pancreato-Biliary Surgery, The Sixth Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Interventional Medicine, The Sixth Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"An","sequence":"additional","affiliation":[{"name":"Senior Department of Hepato-Pancreato-Biliary Surgery, The First Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihan","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Hepato-Pancreato-Biliary Surgery, The Sixth Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7841-6806","authenticated-orcid":false,"given":"Nianxin","family":"Xia","sequence":"additional","affiliation":[{"name":"Senior Department of Hepato-Pancreato-Biliary Surgery, The First Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"bibr1-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.11.002"},{"issue":"1","key":"bibr2-15330338241256812","volume":"1","author":"Liu B","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr3-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00608"},{"key":"bibr4-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00392"},{"key":"bibr5-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.01.041"},{"key":"bibr6-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-4140"},{"key":"bibr7-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1022"},{"key":"bibr8-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03767-4"},{"key":"bibr9-15330338241256812","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"issue":"3","key":"bibr10-15330338241256812","first-page":"833","volume":"21","author":"Chinese Anti-Cancer Association Hepatocellular Carcinoma Professional Committee","year":"2015","journal-title":"Chin J Hepatobiliary Surg"},{"issue":"2","key":"bibr11-15330338241256812","first-page":"85","volume":"4","author":"Yang XN","year":"2004","journal-title":"Evid Based Med"},{"issue":"6","key":"bibr12-15330338241256812","first-page":"633","volume":"20","author":"Yue JJ","year":"2018","journal-title":"Southeast Defense Med"},{"key":"bibr13-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.01.013"},{"key":"bibr14-15330338241256812","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.869993"},{"key":"bibr15-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021200153"},{"key":"bibr16-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004350"},{"key":"bibr17-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.211806"},{"key":"bibr18-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00808"},{"key":"bibr19-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01029-3"},{"key":"bibr20-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01642-1"},{"key":"bibr21-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13806"},{"key":"bibr22-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.03.039"},{"key":"bibr23-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1698"},{"key":"bibr24-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24386-0"},{"key":"bibr25-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32613"},{"key":"bibr26-15330338241256812","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01868-2"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338241256812","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338241256812","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338241256812","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:14:50Z","timestamp":1777702490000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338241256812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":26,"alternative-id":["10.1177\/15330338241256812"],"URL":"https:\/\/doi.org\/10.1177\/15330338241256812","relation":{},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"15330338241256812"}}